Simulations Plus Releases ADMET Predictor Version 7.1
Upgrade extends technological lead, adds several user-requested functions
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical discovery and development, today announced that it has released version 7.1 of its best-in-class ADMET Predictor™ molecular property prediction software.
“Industry scientists increasingly prefer automating analyzing and reporting scientific data. KNIME is an open automation platform whose significance has been steadily growing over the past few years. ADMET Predictor now seamlessly incorporates itself into both KNIME and the popular commercial platform called Pipeline Pilot™.”
Dr. Robert Fraczkiewicz, team leader for ADMET Cheminformatics at Simulations Plus, said, “The release of ADMET Predictor 7.1 adds several functions requested by our users around the world, including:
- Ability to run under the KNIME workflow manager in addition to Pipeline Pilot™
- Output options now provide enhanced access to the new pKa model released in version 7.0
- Improvements to several aspects of the graphical user interface (GUI)
- Additional command-line options
- Improvements to the ADMET Modeler™ model-building subprogram
- Improved integration with our GastroPlus™ software”
Dr. Fraczkiewicz continued, “Industry scientists increasingly prefer automating analyzing and reporting scientific data. KNIME is an open automation platform whose significance has been steadily growing over the past few years. ADMET Predictor now seamlessly incorporates itself into both KNIME and the popular commercial platform called Pipeline Pilot™."
Mr. John DiBella, vice president for marketing and sales for Simulations Plus, added: “This interim release of ADMET Predictor addresses a number of requested features that we wanted to deploy to our users as soon as possible rather than wait for the next major release. ADMET Predictor continues to enjoy its industry-leading reputation for predictive accuracy and computational speed, and was a key product in our recent malaria and COX-2/COX-1 NCE (new chemical entity) projects. This release demonstrates our commitment to maximizing the productivity of our users as quickly as possible.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Our recently announced acquisition of Cognigen, Inc. of Buffalo, NY, expected to close on September 2, will add top-quality clinical trial data analysis to our offerings, and will more than double our staff from 30 to 65, add nearly 50% to revenues, and add to earnings in the coming fiscal year that begins September 1. We also provide a productivity tool called Abbreviate! for PCs. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.